RNA interference mediated inhibition of checkpoint kinase-1...

Details RNA interference mediated inhibition of checkpoint kinase-1... RNA interference mediated inhibition of checkpoint kinase-1...

2009-12-17

2010-12-21

Chong, Kimberly (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S024310, C536S024100, C514S04400A, C435S006120, C435S325000, C435S375000

Reexamination Certificate

active

07855284

ABSTRACT:
This invention relates to compounds, compositions, and methods useful for modulating checkpoint kinase (e.g., checkpoint kinase-1 or CHK-1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of checkpoint kinase gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of checkpoint kinase genes.

REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 2003/0083294 (2003-05-01), Sullenger et al.
patent: 2004/0053875 (2004-03-01), Kreutzer et al.
patent: 2004/0259247 (2004-12-01), Tusch et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: WO90/14090 (1990-11-01), None
patent: WO94/01550 (1994-01-01), None
patent: WO99/32619 (1999-07-01), None
patent: WO99/49029 (1999-09-01), None
patent: WO00/01846 (2000-01-01), None
patent: WO00/44895 (2000-08-01), None
patent: WO00/44914 (2000-08-01), None
patent: WO01/36646 (2001-05-01), None
patent: WO01/96584 (2001-12-01), None
patent: WO02/22636 (2002-03-01), None
patent: WO02/44321 (2002-06-01), None
patent: WO03/64626 (2003-08-01), None
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,”Oligonucleotides13(5):303-312 (2003).
Bass et al. “The Short Answer,”Nature411:428-429 (2001).
Braasch et al. “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,”Biochem. 41(14):4503-4510 (2002).
Caplen “RNAi as a Gene Therapy Approach,”Expert Opin. Biol. Thera. 3(4):575-586 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,”Methods26(2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,”EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,”Nucleic Acids Research Supplement2:251-252 (2002).
Hu et al. “The Radioresistance toKilling of A1-5 Cells Derives from Activation of the Chk1 Pathway,”J. Biol. Chem. 276(21):17693-17698 (2001).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/04448, 2 pages.
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,”Biochemical and Biophysical Research Communications295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,”Biochemical and Biophysical Research Communications281:639-644 (2001).
Luo et al. “Blocking CHK1 Expression Induces Apoptosis and Abrogates the G2 Checkpoint Mechansim,”Neoplasia3(5):411-419 (2001).
Olie et al. “Analysis of ribosyl-modified, mixed backbone analogs of bcl-2/bcl-xL, antisense oligonucleotide,”Biochimica et Biophysica Acta1576:101-109 (2002).
Parrish et al. “Functional Anatomy of a dsRNA trigger: differential requirements for the two trigger strands in RNA interference,”Mol. Cell. 6:1077-1087 (2000).
Pieken et al. “Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes,”Science253:314-317 (1991).
Shieh et al. “The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phophorylate p53 at multiple DNA damage-inducible sites,”Genes and Dev. 14:289-300 (2000).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,”Molecular Interventions295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,”Genes and Development13(24):3191-3197 (1999).
www.dictionary.reference.com Jun. 23, 2006.
Yu et al. “Antisense Inhibition of Chk2/hCds1 Expression Attenuates DNA Damage-Induced S and G2 Checkpoints and Enhances Apoptotic Activity in HEK-293 Cells,”FEBS Letters505(1):7-12 (2001).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed on May 2, 2006 for U.S. Appl. No. 10/898,660, 18 pages.
Office Action mailed on Jul. 17, 2006 for U.S. Appl. No. 10/898,660, 6 pages.
Office Action mailed on Jul. 11, 2007 for U.S. Appl. No. 11/448,115, 19 pages.
Office Action mailed on Jul. 9, 2008 for U.S. Appl. No. 11/448,115, 26 pages.
Office Action mailed on Apr. 2, 2009 for U.S. Appl. No. 12/203,669, 21 pages.

Affiliated with

Also associated with

Rating

RNA interference mediated inhibition of checkpoint kinase-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RNA interference mediated inhibition of checkpoint kinase-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of checkpoint kinase-1... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4162171